Eloralintide
Evidence: B+ — Meaningful Human EvidenceMetabolic / Weight Management
Evidence Snapshot
What this grade covers
SC monotherapy -- Phase 1b and full 48-week Phase 2, both peer-reviewed and integrity-clear on direct database check, plus exact-subject selectivity data. No oral program exists. Combination-with-tirzepatide data is development-status only and does not contribute to this grade.
Regulatory Context
Eloralintide is investigational. No approval was identified in the verified searches used for this review in any jurisdiction. A Phase 3 monotherapy program and several label-expansion studies are underway; none have reported results. Separate trials studying eloralintide in combination with tirzepatide are also underway and are development-status only.
Research Takeaway
Eloralintide (LY3841136) is a long-acting, SELECTIVE amylin-receptor agonist peptide, showing 12-fold selectivity for the amylin receptor over the calcitonin receptor and 11-fold over AMY3R in human in vitro assays.
Evidence boundary: Selectivity data is in vitro/preclinical; pair with clinical AE data before drawing safety conclusions.
See all 5 evidence claims →Quick Summary
Eloralintide (LY3841136) is a long-acting, selective amylin-receptor agonist peptide developed by Eli Lilly. In a 48-week Phase 2 trial, it produced mean body-weight reductions of approximately 9% to 20% versus 0.4% with placebo in adults with obesity or overweight. Its receptor selectivity (12-fold over the calcitonin receptor) distinguishes it from dual amylin/calcitonin agonists and from Amycretin, a broader triple-receptor agonist. Eloralintide is investigational, with a Phase 3 monotherapy program underway; it is also being studied in combination with tirzepatide in separate, still-unpublished trials.
Mechanism & Research Overview
Eloralintide (LY3841136) is a long-acting, SELECTIVE amylin-receptor agonist, showing 12-fold selectivity for the amylin receptor over the calcitonin receptor and 11-fold over AMY3R in human in vitro assays. This selectivity distinguishes it from dual amylin/calcitonin (DACRA-like) agonists and from Amycretin, which engages the calcitonin receptor as well as GLP-1 and amylin receptors.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Eloralintide (LY3841136) is a long-acting, SELECTIVE amylin-receptor agonist peptide, showing 12-fold selectivity for the amylin receptor over the calcitonin receptor and 11-fold over AMY3R in human in vitro assays.
Does not establish
Evidence boundary: Selectivity data is in vitro/preclinical; pair with clinical AE data before drawing safety conclusions.
Supported
In a 48-week Phase 2 RCT, SC eloralintide monotherapy produced mean body-weight reductions of approximately 9% to 20% across dose/regimen arms, versus 0.4% with placebo, in adults with obesity or overweight plus at least one weight-related comorbidity, without diabetes.
Does not establish
Evidence boundary: Responder-rate percentages are not frozen -- do not author them until independently verified.
Supported
In a 12-week Phase 1b RCT, the most commonly reported adverse events with SC eloralintide were decreased appetite (19%), headache (12%), fatigue (11%), diarrhea (10%), nausea (8%), and vomiting (4%).
Does not establish
Evidence boundary: Injection-site-reaction, mood-related-event, and pulse-rate-decrease figures are not frozen -- do not author them as confirmed figures.
Supported
Eloralintide is pharmacologically distinct from cagrilintide and pramlintide (both less receptor-selective amylin-pathway agents) and from Amycretin/zenagamtide (a triple-receptor GLP-1/amylin/calcitonin agonist) -- eloralintide's own discovery pharmacology describes a favorable, though not directly head-to-head-tested, gastrointestinal tolerability profile relative to other amylin-pathway agents.
Does not establish
Evidence boundary: Do NOT publish a specific percentage comparison against cagrilintide -- only the qualitative statement is verified.
Supported
Eloralintide is investigational; no approval was identified in the verified searches used for this review in any jurisdiction. Separate trials studying eloralintide in combination with tirzepatide are underway and are development-status only -- no combination-trial result may be used to support a monotherapy claim.
Sources: A Phase 1, Open-Label, Single and Multiple Dose Study of Eloralintide, and Eloralintide With Tirzepatide; A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With LY3841136 and Tirzepatide
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
The most common adverse events reported with SC eloralintide in its Phase 1b trial were decreased appetite, headache, fatigue, diarrhea, nausea, and vomiting -- generally mild-to-moderate. Injection-site-reaction, mood-event, and pulse-rate figures remain unconfirmed and are not published here.Safety Consideration
Eloralintide's own discovery pharmacology reports a qualitatively favorable gastrointestinal tolerability profile compared to other amylin-pathway agents, based on receptor selectivity; this has not been confirmed in a head-to-head clinical trial and no specific percentage comparison is verified.Safety Consideration
Eloralintide has been studied in combination with tirzepatide in ongoing trials; no combination-specific safety conclusion can be drawn yet, and any future combination-trial safety finding must not be applied to eloralintide monotherapy.
Research Areas Being Studied
Research areas discussed on this page reflect the Metabolic / Weight Management category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept (2026):
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept (2025):
- Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial (2025):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept | 2026 | 100 adults with obesity or overweight, 3 US sites | Placebo-adjusted weight loss of 2.6%-11.3%, dose-dependent. Dose-proportional pharmacokinetics (AUC and Cmax ratios of dose-normalised geometric means of 1.1 and 1.0 at week 12); no absolute numeric half-life, Tmax, or Cmax values independently confirmed.
| Decreased appetite 19%, headache 12%, fatigue 11%, diarrhea 10%, nausea 8%, vomiting 4% -- directly confirmed. Injection-site reactions (13%), mood-related events (n=4), and pulse-rate decrease (-14.4bpm at 12mg) were reported in Stage 2A discovery but could NOT be independently confirmed from accessible abstract text -- do not publish these three figures as confirmed until a full-text pull verifies them. 78% completion; 13 discontinued for adverse events. | |
| Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept | 2025 | In vitro human/rat receptor assays; in vivo rat/monkey; Phase 1 human cohort of 48 healthy participants | Eloralintide shows 12-fold selectivity for the amylin receptor over the calcitonin receptor and 11-fold over AMY3R in human in vitro assays -- a SELECTIVE amylin-receptor agonist, distinct from dual amylin/calcitonin (DACRA-like) pharmacology. In the human Phase 1 cohort, week-4 weight reduction was 2.5% (4mg) and 4.4% (12mg) vs placebo. Qualitatively described as having fewer gastrointestinal side effects compared to other amylin agonists; this is a qualitative statement only -- a specific quantitative comparator percentage against cagrilintide could not be independently verified in accessible full text and must not be published as a specific number.
| ||
| Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial | 2025 | 263 adults with obesity/overweight plus at least one weight-related comorbidity, non-diabetic, 46 US centers | Mean body-weight reductions of approximately 9% to 20% across dose/regimen arms vs 0.4% with placebo; all arms met the primary endpoint. Favorable cardiometabolic secondary effects (waist circumference, blood pressure, lipids, glycemic markers, inflammation). Responder-rate percentages (e.g. proportion achieving >=20% weight loss) were reported in Stage 2A discovery but could not be independently confirmed from accessible abstract text.
| Nausea and fatigue most common adverse events, mild-to-moderate, dose-related; low-dose arms approximately placebo-level. |
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| A Phase 1, Open-Label, Single and Multiple Dose Study of Eloralintide, and Eloralintide With Tirzepatide | 2026 | 188 participants, 6 cohorts (A-D combination, E-F eloralintide-monotherapy) | Development-status only. Contains genuine eloralintide-monotherapy arms (Cohorts E-F) alongside combination arms, but no results have been posted. Any future combination-arm result must not be used to support an eloralintide monotherapy claim.
| ||
| A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With LY3841136 and Tirzepatide | 2026 | T2D and obesity/overweight population, 10 arms (3 LY3841136-monotherapy doses, combination arms, tirzepatide-monotherapy, placebo) | Development-status only, distinct from the Phase 1 combination PK study (NCT06916065). No results posted. Any future combination-arm result must not be used to support an eloralintide monotherapy claim, and no tirzepatide-arm data from this trial may be used to describe eloralintide.
|
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published research and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated .
Follow research updates for Eloralintide
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.